2.065
price down icon3.50%   -0.075
after-market Dopo l'orario di chiusura: 2.10 0.035 +1.69%
loading
Precedente Chiudi:
$2.14
Aprire:
$2.15
Volume 24 ore:
983.57K
Relative Volume:
0.68
Capitalizzazione di mercato:
$188.58M
Reddito:
-
Utile/perdita netta:
$-192.96M
Rapporto P/E:
-0.6258
EPS:
-3.3
Flusso di cassa netto:
$-167.04M
1 W Prestazione:
-14.32%
1M Prestazione:
+21.47%
6M Prestazione:
-5.71%
1 anno Prestazione:
-8.63%
Intervallo 1D:
Value
$2.06
$2.195
Intervallo di 1 settimana:
Value
$2.05
$2.51
Portata 52W:
Value
$0.783
$3.39

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Nome
Ventyx Biosciences Inc
Name
Telefono
(858) 945-2393
Name
Indirizzo
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Dipendente
79
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
VTYX's Discussions on Twitter

Confronta VTYX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VTYX
Ventyx Biosciences Inc
2.065 188.58M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-03-12 Aggiornamento Oppenheimer Perform → Outperform
2024-03-12 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-11-07 Downgrade H.C. Wainwright Buy → Neutral
2023-11-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-11-07 Downgrade Oppenheimer Outperform → Perform
2023-11-07 Downgrade Stifel Buy → Hold
2023-11-07 Downgrade Wells Fargo Overweight → Equal Weight
2023-06-14 Ripresa Credit Suisse Outperform
2023-03-21 Iniziato Wells Fargo Overweight
2022-12-19 Iniziato Goldman Buy
2022-11-17 Iniziato Morgan Stanley Overweight
2022-09-07 Iniziato Stifel Buy
2022-09-01 Iniziato H.C. Wainwright Buy
2022-05-09 Iniziato Credit Suisse Outperform
2022-03-31 Iniziato Canaccord Genuity Buy
2022-02-01 Iniziato Oppenheimer Outperform
2021-11-15 Iniziato Jefferies Buy
2021-11-15 Iniziato Piper Sandler Overweight
Mostra tutto

Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie

pulisher
Jun 18, 2025

Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 15, 2025

Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria

Jun 15, 2025
pulisher
Jun 12, 2025

Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Ventyx Biosciences reports annual meeting results - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

Piper Sandler maintains $21 target on Ventyx stock - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

As Ventyx Approaches Multiple Phase II Readouts, What Could Be Next For The Stock? - RTTNews

Jun 09, 2025
pulisher
Jun 09, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Has $1.04 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ventyx Biosciences at Jefferies Conference: Strategic Developments in Focus By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Buys 19,982 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 29, 2025
pulisher
May 28, 2025

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Ventyx Biosciences Executives Set for Key Presentation on Autoimmune Drug Pipeline at Jefferies Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 28, 2025
pulisher
May 25, 2025

Bank of America Corp DE Has $9.36 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 25, 2025
pulisher
May 22, 2025

Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews

May 22, 2025
pulisher
May 21, 2025

Spotlight On 3 Penny Stocks With Market Caps Under $500M - simplywall.st

May 21, 2025
pulisher
May 21, 2025

VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

May 21, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Sells 13,616 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 19, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Makes New $347,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 17, 2025
pulisher
May 13, 2025

Barclays PLC Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 13, 2025
pulisher
May 11, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

May 11, 2025
pulisher
May 10, 2025

Mariner LLC Sells 8,485 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

May 10, 2025
pulisher
May 09, 2025

Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Ventyx Biosciences Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Investors who lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Lost Money on Ventyx Biosciences, Inc.(VTYX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Market Resilience: Ventyx Biosciences Inc (VTYX) Finishes Weak at 1.28, Down -5.88 - DWinneX

May 08, 2025
pulisher
May 08, 2025

Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Ratios Uncovered: Breaking Down Ventyx Biosciences Inc (VTYX)’s Trailing Twelve Months Metrics - DWinneX

May 07, 2025
pulisher
May 05, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

May 05, 2025

Ventyx Biosciences Inc Azioni (VTYX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Ventyx Biosciences Inc Azioni (VTYX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mohan Raju
CEO AND PRESIDENT
Mar 28 '25
Option Exercise
0.00
11,844
0
2,303,540
Nuss John
CHIEF SCIENTIFIC OFFICER
Mar 28 '25
Option Exercise
0.00
4,531
0
469,113
Nuss John
CHIEF SCIENTIFIC OFFICER
Dec 27 '24
Sale
2.36
21,119
49,841
464,582
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):